This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Aortic Valve Disease
+2

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Sponsored by Artivion Inc.

About this trial

Last updated a year ago

Study ID

ONX1801.000-C

Status

Terminated

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 3 years ago

What is this trial about?

Currently, warfarin is the only approved anticoagulation for patients with mechanical valves. The purpose of this study is to determine if participants with an On-X Prosthetic Heart Valve / On-X aortic valve can be maintained safely and effectively on apixaban. Both the On-X aortic valve and apixaban have been approved for use by the US Food and Drug Administration (FDA) but they have not been approved to be used together.

What are the participation requirements?

Yes

Inclusion Criteria

- Male or female at least 18 years of age at the time of giving informed consent.

- Participants currently receiving warfarin anticoagulation and who are able to receive warfarin with a target INR 2.0 to 3.0.

- Participants are able to take low-dose aspirin at a dose of 75 -100 mg daily or have a documented contraindication to aspirin use.

- Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.

- Female participants of childbearing potential, including those who are less than 2 years post-menopausal, must agree to, and comply with using a highly effective method of birth control (eg, barrier contraceptives [condom or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices or sexual abstinence) while partaking in this study. In addition, all women of childbearing potential must agree to continue to use birth control throughout the study until last study visit.

- Informed of the full nature and purpose of the study, including possible risks and side effects, given ample time and opportunity to read and understand this information, and sign and date the written informed consent before inclusion in the study.

No

Exclusion Criteria

- Mechanical valve in any position other than aortic valve.

- Any cardiac surgery in the three months (90 days) prior to enrollment.

- Need to be on aspirin >100 mg daily or a P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel, or ticlopidine).

- Known hypersensitivity or other contraindication to apixaban.

- On dialysis or a creatinine clearance < 25 mL/min.

- Ischemic stroke or intracranial hemorrhage within 3 months.

- Active pathological bleeding at the time of screening for enrollment.

- Active endocarditis at the time of screening for enrollment.

- Pregnant, plan to become pregnant, or are breast feeding.

- On concomitant combined strong P-gp and CYP3A4 inducers or inhibitors.

- History of non-compliance with recommended monthly INR testing.

Locations

Location

Status